ronstik/iStock via Getty Images
I’m not exactly surprised that a sub-$1B growth med-tech continues to be overlooked in the market, but Artivion, Inc. (NYSE:AORT) management is doing the right things to continue developing a growth story fueled by data-backed innovative products in cardiac care.
Up more than 70% since my last article, Artivion has handily outperformed its comps, but I don’t think the story is quite done. It doesn’t take particularly ambitious assumptions to support a $30-plus fair value, and I think ongoing execution will get this stock more of its due over the next year or two.
Strong Data Can Drive Share Growth And Market Penetration, Fueling Double-Digit Revenue Growth
Artivion has logged some solid quarterly performances since my last update, with quarterly constant currency revenue growth of 12% (Q3 ’23), 15% (Q4 ’23), and 16% (Q1 ’24) that has surpassed prior sell-side estimates and driven increased guidance…
